BOSTON, August 6, 2026
Praxis Precision Medicines reported its second quarter 2026 financial results, highlighting continued regulatory progress for its two lead central nervous system (CNS) programs, ulixacaltamide HCl for Essential Tremor (ET) and relutrigine for SCN2A and SCN8A developmental and epileptic encephalopathies (DEEs). The company announced that FDA mid-cycle meetings for both New Drug Applications (NDAs) identified no major safety or efficacy concerns, and the agency indicated that no advisory committee meetings are planned. Praxis also confirmed that FDA Bioresearch Monitoring (BIMO) inspections concluded without any Form FDA 483 observations. Supported by approximately $1.4 billion in cash and investments, the company expects to fund operations into 2028 while accelerating commercial launch preparations ahead of anticipated regulatory decisions.
FDA Reviews Progress for Ulixacaltamide and Relutrigine
Praxis reported continued progress for ulixacaltamide HCl, an investigational T-type calcium channel inhibitor being reviewed for the treatment of Essential Tremor, with a PDUFA target action date of January 29, 2027. The company stated that the FDA raised no significant safety or efficacy issues during the mid-cycle review and confirmed that an advisory committee meeting is not expected. Commercial preparations continue to expand through physician education initiatives, distribution planning, inventory build-up, and marketing infrastructure. Meanwhile, relutrigine, a first-in-class state-selective sodium channel modulator for SCN2A and SCN8A DEEs, remains under FDA review with a revised PDUFA date of December 27, 2026 following a major amendment. Praxis also reported enrollment exceeding 200 patients in the EMERALD study evaluating relutrigine across genetically defined developmental epilepsies, with topline results anticipated in the fourth quarter of 2026
Pipeline Expands Across Epilepsy and Rare Neurological Disorders
Beyond its NDA-stage assets, Praxis continued advancing its broader neuroscience portfolio. The company received its third FDA Breakthrough Therapy Designation for elsunersen, an investigational antisense oligonucleotide targeting early-seizure-onset SCN2A developmental and epileptic encephalopathy, following positive EMBRAVE Part A results. Enrollment continues in the registrational EMBRAVE3 study, with topline data expected in 2027. Praxis also provided an update on vormatrigine, its investigational therapy for focal onset seizures and generalized epilepsy, noting that while the POWER1 study did not meet its primary endpoint, it achieved a key secondary endpoint demonstrating significant seizure reduction in many patients. Based on insights from POWER1, the company plans to restart the POWER2 study and initiate POWER3 during the fourth quarter of 2026.
Advertisement
Strong Financial Position Supports Commercial Expansion
Praxis ended the second quarter with approximately $1.4 billion in cash, cash equivalents, and marketable securities, compared with $926.1 million at the end of 2025, primarily reflecting proceeds from its January 2026 public offering. Research and development expenses increased to $69.4 million, driven mainly by continued investment in the Solidus™ antisense platform and personnel growth. General and administrative expenses rose to $27.5 million, reflecting expanded commercial infrastructure and professional services supporting anticipated product launches. The company reported a net loss of $83.7 million for the quarter and stated that its current financial resources are expected to support operations into 2028 while advancing multiple late-stage CNS programs toward commercialization.
Source:Praxis Precision Medicines press release
